Karyopharm Therapeutics Inc. (KPTIQ)
OTCMKTS · Delayed Price · Currency is USD
0.0254
-0.0001 (-0.39%)
At close: Nov 13, 2026
Karyopharm Therapeutics Stock Forecast
OTC-KPTIQ's stock price has decreased by -99.55% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 3 analysts polled by S&P Global, Karyopharm Therapeutics stock has a consensus rating of "Buy" and an average price target of $7.00. The average 1-year stock price forecast is 27,459.06% higher than the current stock price, while the lowest is $3.00 (+11,711.02%) and the highest is $11 (+43,207.09%).
Price Target: $7.00 (+27,459.06%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Karyopharm Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Hold | 1 | 1 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Nov 2, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $8 | Buy | Maintains | $8 | +31,396.06% | Oct 27, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $3.68 | Buy | Maintains | $3.68 | +14,388.19% | Sep 1, 2026 |
| Jefferies | Jefferies | Buy Maintains $14 → $11 | Buy | Maintains | $14 → $11 | +43,207.09% | Jul 31, 2026 |
| Robert W. Baird | Robert W. Baird | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Jul 31, 2026 |
Financial Forecast
Revenue This Year
135.22M
from 146.07M
Decreased by -7.43%
Revenue Next Year
172.74M
from 135.22M
Increased by 27.75%
EPS This Year
-5.68
from -12.22
EPS Next Year
-1.92
from -5.68
EPS and Forward PE are based on non-GAAP adjusted numbers.